ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFNγ-driven immunopathology

  1. Riem Gawish
  2. Philipp Starkl
  3. Lisabeth Pimenov
  4. Anastasiya Hladik
  5. Karin Lakovits
  6. Felicitas Oberndorfer
  7. Shane JF Cronin
  8. Anna Ohradanova-Repic
  9. Gerald Wirnsberger
  10. Benedikt Agerer
  11. Lukas Endler
  12. Tümay Capraz
  13. Jan W Perthold
  14. Domagoj Cikes
  15. Rubina Koglgruber
  16. Astrid Hagelkruys
  17. Nuria Montserrat
  18. Ali Mirazimi
  19. Louis Boon
  20. Hannes Stockinger
  21. Andreas Bergthaler
  22. Chris Oostenbrink
  23. Josef M Penninger
  24. Sylvia Knapp  Is a corresponding author
  1. Medical University of Vienna, Austria
  2. Austrian Academy of Sciences, Austria
  3. Apeiron Biologics AG, Austria
  4. University of Natural Resources and Life Sciences, Austria
  5. Institute for Bioengineering of Catalonia, Spain
  6. Karolinska Institute, Sweden
  7. Polpharma Biologics, Netherlands

Abstract

In silico modelling revealed how only three Spike mutations of maVie16 enhanced interaction with murine ACE2. MaVie16 induced profound pathology in BALB/c and C57BL/6 mice and the resulting mouse COVID-19 (mCOVID-19) replicated critical aspects of human disease, including early lymphopenia, pulmonary immune cell infiltration, pneumonia and specific adaptive immunity. Inhibition of the proinflammatory cytokines IFNg and TNF substantially reduced immunopathology. Importantly, genetic ACE2-deficiency completely prevented mCOVID-19 development. Finally, inhalation therapy with recombinant ACE2 fully protected mice from mCOVID-19, revealing a novel and efficient treatment. Thus, we here present maVie16 as a new tool to model COVID-19 for the discovery of new therapies and show that disease severity is determined by cytokine-driven immunopathology and critically dependent on ACE2 in vivo.

Data availability

maVie16 SARS-CoV-2 genome sequence will be published on: https://www.ebi.ac.uk/enaProjectaccession: PRJEB46926

The following data sets were generated

Article and author information

Author details

  1. Riem Gawish

    Department of Medicine I, Medical University of Vienna, Vienna, Austria
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4267-2131
  2. Philipp Starkl

    Department of Medicine I, Medical University of Vienna, Vienna, Austria
    Competing interests
    No competing interests declared.
  3. Lisabeth Pimenov

    Department of Medicine I, Medical University of Vienna, Vienna, Austria
    Competing interests
    No competing interests declared.
  4. Anastasiya Hladik

    Department of Medicine I, Medical University of Vienna, Vienna, Austria
    Competing interests
    No competing interests declared.
  5. Karin Lakovits

    Department of Medicine I, Medical University of Vienna, Vienna, Austria
    Competing interests
    No competing interests declared.
  6. Felicitas Oberndorfer

    Department of Pathology, Medical University of Vienna, Vienna, Austria
    Competing interests
    No competing interests declared.
  7. Shane JF Cronin

    Institute of Molecular Biotechnology, Austrian Academy of Sciences, Vienna, Austria
    Competing interests
    No competing interests declared.
  8. Anna Ohradanova-Repic

    Molecular Immunology Unit, Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8005-8522
  9. Gerald Wirnsberger

    Apeiron Biologics AG, Vienna, Austria
    Competing interests
    Gerald Wirnsberger, is an employee of Apeiron Biologics. Apeiron holds a patent on the use of ACE2 for the treatment of lung, heart, or kidney injury and is currently testing soluble ACE2 for treatment in COVID-19 patients..
  10. Benedikt Agerer

    CeMM, Research Center for Molecular Medicine, Austrian Academy of Sciences, Vienna, Austria
    Competing interests
    No competing interests declared.
  11. Lukas Endler

    CeMM, Research Center for Molecular Medicine, Austrian Academy of Sciences, Vienna, Austria
    Competing interests
    No competing interests declared.
  12. Tümay Capraz

    Institute for Molecular Modeling and Simulation, University of Natural Resources and Life Sciences, Vienna, Austria
    Competing interests
    No competing interests declared.
  13. Jan W Perthold

    Institute for Molecular Modeling and Simulation, University of Natural Resources and Life Sciences, Vienna, Austria
    Competing interests
    No competing interests declared.
  14. Domagoj Cikes

    Institute of Molecular Biotechnology, Austrian Academy of Sciences, Vienna, Austria
    Competing interests
    No competing interests declared.
  15. Rubina Koglgruber

    Institute of Molecular Biotechnology, Austrian Academy of Sciences, Vienna, Austria
    Competing interests
    No competing interests declared.
  16. Astrid Hagelkruys

    Institute of Molecular Biotechnology, Austrian Academy of Sciences, Vienna, Austria
    Competing interests
    No competing interests declared.
  17. Nuria Montserrat

    Pluripotency for Organ Regeneration, Institute for Bioengineering of Catalonia, Barcelona, Spain
    Competing interests
    No competing interests declared.
  18. Ali Mirazimi

    Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden
    Competing interests
    No competing interests declared.
  19. Louis Boon

    Polpharma Biologics, Utrecht, Netherlands
    Competing interests
    No competing interests declared.
  20. Hannes Stockinger

    Molecular Immunology Unit, Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6404-4430
  21. Andreas Bergthaler

    CeMM, Research Center for Molecular Medicine, Austrian Academy of Sciences, Vienna, Austria
    Competing interests
    No competing interests declared.
  22. Chris Oostenbrink

    Institute for Molecular Modeling and Simulation, University of Natural Resources and Life Sciences, Vienna, Austria
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4232-2556
  23. Josef M Penninger

    Institute of Molecular Biotechnology, Austrian Academy of Sciences, Vienna, Austria
    Competing interests
    Josef M Penninger, declares a conflict of interest as a founder and shareholder of Apeiron Biologics. Apeiron holds a patent on the use of ACE2 for the treatment of lung, heart, or kidney injury and is currently testing soluble ACE2 for treatment in COVID-19 patients.(patent #WO2021191436A1)..
  24. Sylvia Knapp

    Department of Medicine I, Medical University of Vienna, Vienna, Austria
    For correspondence
    Sylvia.knapp@meduniwien.ac.at
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9016-5244

Funding

Austrian Science Fund (F54-10 and F61-04)

  • Sylvia Knapp

Innovative Medicines Initiative (101005026)

  • Josef M Penninger

Austrian Science Fund (ZK57-B28)

  • Riem Gawish

Austrian Science Fund (P31113-B30)

  • Philipp Starkl

Austrian Science Fund (P 34253-B)

  • Anna Ohradanova-Repic

Austrian Science Fund (P 34253-B)

  • Hannes Stockinger

Austrian Science Fund (DK W1212)

  • Benedikt Agerer

Austrian Science Fund (Z 271-B19)

  • Josef M Penninger

Canada Research Chairs (F18-01336)

  • Josef M Penninger

Canadian Institutes of Health Research (F20-02343 and F20-02015)

  • Josef M Penninger

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All experiments involving SARS-CoV-2 or its derivatives were performed in Biosafety Level 3 (BSL-3) facilities at the Medical University of Vienna and performed according to the ethical guidelines and after approval by the institutional review board of the Austrian Ministry of Sciences (BMBWF-2020-0.253.770) and in accordance with the directives of the EU.

Copyright

© 2022, Gawish et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,067
    views
  • 544
    downloads
  • 52
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Riem Gawish
  2. Philipp Starkl
  3. Lisabeth Pimenov
  4. Anastasiya Hladik
  5. Karin Lakovits
  6. Felicitas Oberndorfer
  7. Shane JF Cronin
  8. Anna Ohradanova-Repic
  9. Gerald Wirnsberger
  10. Benedikt Agerer
  11. Lukas Endler
  12. Tümay Capraz
  13. Jan W Perthold
  14. Domagoj Cikes
  15. Rubina Koglgruber
  16. Astrid Hagelkruys
  17. Nuria Montserrat
  18. Ali Mirazimi
  19. Louis Boon
  20. Hannes Stockinger
  21. Andreas Bergthaler
  22. Chris Oostenbrink
  23. Josef M Penninger
  24. Sylvia Knapp
(2022)
ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFNγ-driven immunopathology
eLife 11:e74623.
https://doi.org/10.7554/eLife.74623

Share this article

https://doi.org/10.7554/eLife.74623

Further reading

    1. Immunology and Inflammation
    Zhiyan Wang, Nore Ojogun ... Mingfang Lu
    Research Article

    The incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) has been increasing worldwide. Since gut-derived bacterial lipopolysaccharides (LPS) can travel via the portal vein to the liver and play an important role in producing hepatic pathology, it seemed possible that (1) LPS stimulates hepatic cells to accumulate lipid, and (2) inactivating LPS can be preventive. Acyloxyacyl hydrolase (AOAH), the eukaryotic lipase that inactivates LPS and oxidized phospholipids, is produced in the intestine, liver, and other organs. We fed mice either normal chow or a high-fat diet for 28 weeks and found that Aoah-/- mice accumulated more hepatic lipid than did Aoah+/+ mice. In young mice, before increased hepatic fat accumulation was observed, Aoah-/- mouse livers increased their abundance of sterol regulatory element-binding protein 1, and the expression of its target genes that promote fatty acid synthesis. Aoah-/- mice also increased hepatic expression of Cd36 and Fabp3, which mediate fatty acid uptake, and decreased expression of fatty acid-oxidation-related genes Acot2 and Ppara. Our results provide evidence that increasing AOAH abundance in the gut, bloodstream, and/or liver may be an effective strategy for preventing or treating MASLD.

    1. Immunology and Inflammation
    2. Microbiology and Infectious Disease
    Malika Hale, Kennidy K Takehara ... Marion Pepper
    Research Article

    Pseudomonas aeruginosa (PA) is an opportunistic, frequently multidrug-resistant pathogen that can cause severe infections in hospitalized patients. Antibodies against the PA virulence factor, PcrV, protect from death and disease in a variety of animal models. However, clinical trials of PcrV-binding antibody-based products have thus far failed to demonstrate benefit. Prior candidates were derivations of antibodies identified using protein-immunized animal systems and required extensive engineering to optimize binding and/or reduce immunogenicity. Of note, PA infections are common in people with cystic fibrosis (pwCF), who are generally believed to mount normal adaptive immune responses. Here, we utilized a tetramer reagent to detect and isolate PcrV-specific B cells in pwCF and, via single-cell sorting and paired-chain sequencing, identified the B cell receptor (BCR) variable region sequences that confer PcrV-specificity. We derived multiple high affinity anti-PcrV monoclonal antibodies (mAbs) from PcrV-specific B cells across three donors, including mAbs that exhibit potent anti-PA activity in a murine pneumonia model. This robust strategy for mAb discovery expands what is known about PA-specific B cells in pwCF and yields novel mAbs with potential for future clinical use.